1492 Capital Management LLC purchased a new position in Revance Therapeutics Inc (NASDAQ:RVNC) during the 4th quarter, Holdings Channel reports. The fund purchased 38,966 shares of the biopharmaceutical company’s stock, valued at approximately $1,393,000. Revance Therapeutics comprises approximately 1.1% of 1492 Capital Management LLC’s portfolio, making the stock its 29th biggest position.
Several other large investors have also added to or reduced their stakes in RVNC. Vanguard Group Inc. lifted its stake in shares of Revance Therapeutics by 7.3% in the second quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock worth $24,595,000 after acquiring an additional 63,505 shares in the last quarter. Parametric Portfolio Associates LLC lifted its stake in shares of Revance Therapeutics by 6.2% in the second quarter. Parametric Portfolio Associates LLC now owns 29,112 shares of the biopharmaceutical company’s stock worth $769,000 after acquiring an additional 1,711 shares in the last quarter. Voya Investment Management LLC acquired a new position in shares of Revance Therapeutics in the second quarter worth about $274,000. State Street Corp lifted its stake in shares of Revance Therapeutics by 0.6% in the second quarter. State Street Corp now owns 452,490 shares of the biopharmaceutical company’s stock worth $11,944,000 after acquiring an additional 2,637 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Revance Therapeutics by 7.5% in the second quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock worth $483,000 after acquiring an additional 1,275 shares in the last quarter. Institutional investors and hedge funds own 95.14% of the company’s stock.
Several research firms recently commented on RVNC. Cantor Fitzgerald set a $50.00 price target on Revance Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, December 13th. Mizuho began coverage on Revance Therapeutics in a research note on Thursday, November 16th. They issued a “buy” rating and a $37.00 price target on the stock. Piper Jaffray Companies set a $48.00 price target on Revance Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Finally, Barclays began coverage on Revance Therapeutics in a research note on Monday, November 27th. They issued an “overweight” rating and a $31.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $45.45.
Shares of Revance Therapeutics Inc (NASDAQ:RVNC) opened at $33.70 on Tuesday. The firm has a market capitalization of $1,201.43, a PE ratio of -8.45 and a beta of 1.36. Revance Therapeutics Inc has a fifty-two week low of $18.00 and a fifty-two week high of $37.45.
Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.09 million. Revance Therapeutics had a negative net margin of 46,025.57% and a negative return on equity of 64.40%. The firm’s quarterly revenue was down 50.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.95) earnings per share. sell-side analysts anticipate that Revance Therapeutics Inc will post -3.64 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “1492 Capital Management LLC Invests $1.39 Million in Revance Therapeutics Inc (RVNC)” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2018/03/13/1492-capital-management-llc-invests-1-39-million-in-revance-therapeutics-inc-rvnc.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics Inc (NASDAQ:RVNC).
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.